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Background: Cystic ﬁbrosis (CF) spans a wide spectrum. Therefore, benchmarking between registries implies comparing similar cohorts.
Objective and methods: Explore patient characteristics in Belgian (B), French (F), German (G) and Dutch (NL) registries (total N = 13,122) and
determine whether they fulﬁll predeﬁned diagnostic criteria.
Results: Using as case deﬁnition sweat chloride N60 mmol/L or 2 CFTR mutations identiﬁed, CF diagnosis was not documented in 2.8, 5.7, 6.5
and 21.6% of subjects in the F, B, NL, and G registries. Restricting CFTR mutation interpretation to 124 CF causing mutations in CFTR2, these
numbers rose to 10.5, 10.4, 14.5 and 24.3% respectively. Excluding these subjects impacted on outcomes. The impact differed between countries;
the largest changes seen were a decrease in % adults from 51.9 to 47.8% in G, a decrease in % pancreas sufﬁciency from 17.0 to 13.0 in F, an
increase in % homozygous for F508del from 55.3 to 63.7 in NL and a decrease of % with sweat chloride ≤60 mmol/L from 8.4 to 1.1 in B.
Conclusion: CF diagnosis is not documented in 10 to 24% of patients included in CF registries. Excluding these patients for analyses leads to
signiﬁcant changes in outcomes.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Diagnosis; Registry1. Introduction
For decades the diagnosis cystic fibrosis (CF) was based on
the typical clinical picture of chronic airway infection and
pancreatic insufficiency. The clinical suspicion of CF was then
confirmed by the abnormal sweat test result. Since the discovery
of the CFTR gene, it has however become obvious that the
disease CF spans a wide spectrum. CFTR mutations have been
described not only in subjects with prototype disease, but also in⁎ Corresponding author at: Public Health and Surveillance, Scientific Institute
of Public Health (WIV-ISP), Rue J. Wytsman, 14, 1050 Brussels, Belgium
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http://dx.doi.org/10.1016/j.jcf.2013.10.010.lishedadults with minimal disease expression or single organ diseases,
which – if patients do not fulfil CF diagnostic criteria – are
referred to as CFTR related disorders [1,2]. Not surprisingly
therefore, opinions differ as to who should or should not be
considered to have the disease CF. In the European diagnostic
consensus, the diagnosis of CF requires ‘compatible symptoms’
plus a sweat chloride value above 60 mmol/L or the presence of 2
CF causing mutations [3]. The diagnosis atypical CF is reserved
for patients with a sweat chloride value in the normal or
intermediate range (30–60 mmol/L) and in whom 2 CF causing
mutations have been identified [3]. The latter patients have
indeed as a group a milder phenotype [4]. Others use a different
sweat chloride cut-off: 30 in newborns and 40 mmol/L in later
life [5].by Elsevier B.V. All rights reserved.
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(www.genet.sickkids.on.ca/app), not necessarily all disease caus-
ing, the definition of CF can lead to debate. Using data in existing
patient registries, the CFTR2 project [6] describes the phenotype
associated with CFTR mutations that have a frequency above
0.01% and compares it with the phenotype of patients homozy-
gous or compound heterozygous for the 23 mutations considered
as CF causing by the American College of Medical Genetics [7].
As such, according to CFTR2, only 124 CFTR mutations of the
160 examined are considered CF disease causing. This limited list
can be used towards a much more restricted CF diagnosis.
Although some CF patient registries may outline a CF case
definition, it is not certain that clinicians submitting cases to the
registries comply with this. If registries include patients with
atypical CF or CFTR-related disorders, patients with mutations of
doubtful clinical consequence or patients in whom the diagnosis
is not documented, this may have an effect on survival analyses
or assessment of disease outcome over time. Since registry data
are increasingly used for benchmarking, selecting similar patient
cohorts is a prerequisite for reliable comparisons between centers
or countries.
The objective of this study is therefore to describe the patients
included in 4 national CF registries (Belgium, France, Germany,
the Netherlands) and to determine if they fulfill predefined CF
diagnostic criteria. In addition we want to assess whether the in-
or exclusion of patients who do not fulfill diagnostic criteria
influences the outcomes calculated in these CF registries.
2. Patients and methods
The 2009 data sets of four national CF registries were
examined: Belgium (B), France (F), Germany (G) and the
Netherlands (NL). None of these registries list or post a specific
CF case definition. In their yearly report these registries state
that they contain information on the subjects with CF known to
and treated in their country's CF centers. The 4 registries are
compliant with national data protection laws. In F, newborn
screening for CF was installed since 2002, and has occurred
nationwide since 2003. In the other countries studied, regional
pilot screening programs have been performed, but in 2009
nationwide newborn screening was not implemented.
For this study, the patients were considered as fulfilling the
diagnostic criteria for CF if their sweat chloride value was
N60 mmol/L or if 2 CFTR mutations were reported in the
registry. In a second more restrictive analysis the diagnosis of CF
required a sweat chloride value above 60 mmol/L or the presence
of 2 of the 124 CF disease causing mutations according to the
CFTR2 project (http://www.cftr2.org/-last accessed June 2013);
these 124 mutations are listed in the addendum of the online
supplement.
In all registries, sweat chloride values obtained via pilocarpine
iontophoresis were analyzed; if several values were available, the
instruction was to report the first test result.
The following additional variables were analyzed: age,
pancreatic status, forced expiratory volume in 1 s (FEV1),
Pseudomonas aeruginosa (PA) colonization status and number
of patients with lung transplant. Age was defined as the ageon December, 31st 2009. Exocrine pancreatic sufficiency
(PS) was defined as fat absorption N93% or fecal fat loss
b7 g/day or fecal elastase level above 200 μg/g in the B and F
registries and as no intake of pancreatic enzymes in the G and
NL registries. FEV1 was expressed as percentage predicted FEV1
(FEV1% predicted) using the Wang and Hankinson references
[8,9]. In the B and NL registries, the best value of the year is
reported; in the F registry the last value of the year; and in the G
registry the value closest to the patient's birthday. Chronic PA
infection was defined according to the Leeds criteria [10] for all
the registries except the G registry where the patients were
considered as chronically infected if PA was found at least once
per year in 2007, 2008 and 2009.
3. Statisitics
Results were expressed per country as median plus interquar-
tile range (IQR) and percentages plus 95% confidence intervals
(CI) unless otherwise specified. Differences between registries
were considered significant when 95% CI did not overlap.
Analyses were done centrally for B and G; and in F and NL
analysis was done by the country's registry team. All analyses
were done using Stata 10 (B, G), SAS 9.2 (F) or SPSS 15.0 (NL).
4. Results
In total, 13,122 CF patients were included in the analysis:
1129 subjects from Belgium, 5640 from France, 5054 from
Germany and 1299 from the Netherlands.
4.1. Availability and interpretation of diagnostic test results: sweat
chloride values and CFTR mutation analysis (Tables 1 and 2)
The proportion of subjects with at least one diagnostic test
result reported was significantly lower in G and NL (see
percentages and confidence intervals not overlapping). Within
every country, sweat chloride value reporting was significantly
lower than CFTR mutation result reporting.
Sweat chloride values were reported in only 40% and 33% of
the patients in G and NL respectively; this was significantly
higher in the B and F registries (CI's not overlapping). Inclusion
of subjects with sweat chloride values ≤60 mmol/L was also
significantly higher in B and F.
Reporting at least oneCFTRmutation was significantly higher
in F and significantly lower in G. Likewise percentage of subjects
with 2CFTRmutations reported was significantly higher in F and
lower in G. When only CF causing mutations as defined by
CFTR2 were considered, the proportion of subjects with 2 CF
causing mutations was significantly higher in NL (81.4%) and
significantly lower in G (62.5%). The percentage of subjects with
at least 1 non CF causing mutation was significantly higher in F
(18.5%) and significantly lower in G (5.0%).
By combining the results of sweat chloride and CFTR
mutation analysis, the percentage of patients without documen-
tation of CF diagnosis can be evaluated (Table 2). Even when
all CFTR mutations detected were considered as proof of
diagnosis, there was no documentation of CF diagnosis in 2.8 to
Table 1
Percentage (95% CI) of patients in whom specific diagnostic test results are reported.
Belgium
N = 1129
France
N = 5640
Germany
N = 5054
The Netherlands
N = 1299
Sweat chloride or at least 1 CFTR mutation 99.0
(98.3–99.5)
98.8
(98.4–99.0)
87.2
(86.2–88.1)
93.8
(92.3–95.0)
Sweat chloride 81.0
(78.5–83.2)
72.1
(70.1–73.3)
40.1
(38.8–41.5)
32.9
(30.4–35.6)
Sweat chloride ≤60 mmol/L 8.4
(6.9–10.2)
6.9
(6.2–7.6)
2.1
(1.7–2.5)
1.7
(1.1–2.6)
At least 1 CFTR mutation 95.5
(94.1–96.6)
97.1
(96.6–97.5)
81.3
(80.2–82.4)
92.8
(91.3–94.2)
2 CFTR mutations 87.4
(85.3–89.3)
93.9
(93.3–94.5)
67.5
(66.2–68.8)
91.1
(89.5–92.6)
2 CF causing mutations 76.4
(73.8–78.9)
75.4
(74.3–76.5)
62.5
(61.1–63.9)
81.4
(79.2–83.5)
1 or 2 non CF causing mutations 11.0
(9.2–13)
18.5
(17.5–19.5)
5.0
(4.3–5.6)
9.7
(8.1–11.4)
Percentages based on the total number of patients in each registry.
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only CF causing mutations listed in CFTR2 were considered as
proof of CF diagnosis. The difference in diagnostic conclusion
between bothCFTRmutation interpretations was lowest in G and
highest in NL and F.
4.2. Demographic and clinical characteristics of patients in 4
national CF registries (Tables 3 and 4)
4.2.1. Comparison of subjects with CF diagnosis not documented
(Table 3) with all subjects included in the registry (Table 4)
When comparing subjects with CF diagnosis not document-
ed to all the patients included in the registry, the proportion of
subjects older than 18 years was significantly higher in all
countries except in B. In all registries the proportion of patients
with sweat chloride below 60 mmol/L was significantly higher
as well as the proportion of subjects with PS (almost more than
twice in G and NL and more than 3 times in B and F). Only in
B, the proportion of subjects with chronic PA colonization was
significantly lower and the mean FEV1 was significantly
higher.
4.2.2. Within registry comparison of results before and after
exclusion of subjects with diagnosis not documented (Table 4)
Excluding patients with diagnosis not documented leads to
following changes: except in B, proportion of adults decreases
slightly but significantly in G; proportion of subjects with sweat
chloride ≤60 mmol/L decreases in all countries (statistically
significant in all except in NL); proportion of subjects homozy-
gous for F508del increases in all countries (significant in all except
in B); proportion with PS decreases in all (significant in F and G).
4.2.3. Comparison between registries before and after exclusion
of subjects with diagnosis not documented (table 4)
The proportion of patients ≥18 years was significantly lower
(CI do not overlap) in F and this remained after exclusion of
subjects with CF diagnosis not documented in the registry. The
proportion of subjects with sweat chloride below 60 mmol/L was
significantly higher in B and F and after exclusion of subjectswith diagnosis not documented this difference was still sig-
nificant for F. The proportion of F508del homozygous patients
was significantly higher in NL before as well as after exclusion.
Only before exclusion of subjects with diagnosis not documented
the proportion of subjects with PS was significantly higher in F
compared to Germany. The percentage of patients with chronic
PAwas significantly higher in NL before (all countries) as well as
after this exclusion (all except B); it was significantly lower in F
before and after this exclusion. Mean FEV1 was significantly
higher in B, before as well as after this exclusion.
5. Discussion
We report the characteristics of the 13,122 patients included in
4 national CF registries in 2009. Clear documentation of the CF
diagnosis is absent in a substantial proportion of subjects included.
In addition, this proportion varies widely between registries and
according to the criteria used. When lenient criteria for CF
diagnosis are used (all subjects with sweat chloride N60 mmol/L
or 2 CFTRmutations reported), proof of CF diagnosis is absent in
2.8% of French subjects up to 21.6% of German subjects. With
stricter criteria of CF diagnosis (all subjects with sweat chloride
N60 mmol/L or 2 CFTR mutations considered CF causing in
CFTR2), these numbers increase to 10.4% and 10.5% in Belgian
and French registries and to 14.5 and 24.3% in the Dutch and
German registries respectively.
The profile of patients with CF diagnosis not documented
differs from that of the ‘average’ subject in the CF registry. In
every registry, the former seems to be a mixture of subjects with
lacking diagnostic test and a severe phenotype and subjects with a
mild phenotype (see tables 3 and 4). However, the ‘enrichment’
with subjects with mild phenotype seems larger in the registries
with more complete reporting of diagnostic tests like F and B
(table 3). These data plead for more accurate documentation of
diagnostic criteria in CF registries and for stratification of patient
cohorts by diagnostic criteria when outcomes are compared
between registries.
Do patients without documented CF diagnosis have CF or
not? Many or at least some of them may well have CF but the
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278 M. Thomas et al. / Journal of Cystic Fibrosis 13 (2014) 275–280supporting data have not been reported, or their mutations have
not been studied to confirm they cause CF, or theymay have been
diagnosed by in vivo or ex vivo CFTR bio-assays like nasal
potential difference or intestinal current measurements (the latter
rarely available in national CF registries). It may be impossible to
answer this question, but still we should ask ourselves whether
these patients should or should not be excluded from analysis of
registry data? Their in- or exclusion does cause a selection bias
and impacts on commonly used descriptors of a CF cohort such
as proportion of adults, pancreatic status, proportion with chronic
PA infection and mean FEV1.
Before designing a common definition of who should be
analyzed in CF registries, we thus need to improve on the
documentation of the CF diagnostic tests in registries. It will
not be easy to avoid missing data. The lack of sweat chloride
results is to some degree understandable and these are usually not
included in CF registry reports. Often the sweat test was done at
time of diagnosis, possibly decades earlier. At present however,
full genotyping should be done and be available in every patient
with CF. Indeed, drugs are available or under development for
patients carrying specific mutations [11]. Therefore, missing data
cannot only preclude accurate classification of patients in CF
registries, but could also impact on the patient's optimal treatment.
The ECFS-Patient Registry report 2008–2009 [12] listed the
percentage of genotyped patients per country (85–100%) and the
reported percentage of two known mutations (43–98%). The
Australian CF data registry 2011 [13] reported, that 96% of all
patients diagnosed in 2011 were genotyped (in contrast to 82.3%
of all reported patients) and that 10 out of the 74 patients
diagnosed in 2011 (13.5%) have a sweat chloride b60 mmol/l.
The Canadian report 2011 states a genotyping rate of 95% [14].
The Cystic Fibrosis Foundation to the Center Directors report
2011 mentions a percentage of patients with sweat test under
60 mmol/L of 5.3% (www.cff.org).
Even with full diagnostic information available, we need to
agree on CF diagnostic criteria for the use of patient registries,
the most complex being the interpretation of CFTR mutations.
For the current analysis, the strict criteria of CFTR2 were used
(average sweat chloride above 60 mmol/L plus functional and
epidemiological proof) [6]. Allowing a more liberal interpreta-
tion of which mutation can be considered disease causing might
allow inclusion of more patients, possibly also patients with
mild phenotype or even doubtful diagnosis, as described in
France for the R117H mutation [15]. Being more restrictive
results in the exclusion of a substantial number of patients from
the analysis. One way to solve this dilemma would be to rely as
much as possible on sweat test results rather than on genetic
analysis to document the diagnosis; of course CFTR2 is already
heavily biased towards sweat chloride results. Relying only on
clinical characteristics to support the diagnosis of CF could lead
to overdiagnosis. Another possibility could be to limit the
comparisons to subsets of patients e.g. homozygous F508del, at
least in Northern countries.
We did find differences between the national CF registries.
Germany and the Netherlands had a higher percentage of
patients with sweat chloride values not reported. In Belgium and
France, the proportion of patients with a sweat chloride values
Table 3
Characteristics of patients with CF diagnosis not documented. Percent (95% CI) unless stated otherwise.
Belgium France Germany The Netherlands
N (% of patients in registry) 117 (10.4) 593 (10.5) 1230 (24.3) 188 (14.5)
Males 46.2 (36.9–55.6) 51.6 (47.5–55.7) 52.8 (50.0–55.7) 52.1 (44.7–59.5)
Median age (yr) (IQR) 17.7 (9.5–32.4) 21.2 (8.9–33.3) 22.3 (14.2–31.1) 25.8 (13.3–38.5)
≥18 year 48.7 (39.4–58.1) 59.7 (55.7–63.6) 64.9 (62.2–67.6) 72.3 (65.4–78.6)
Sweat Cl ≤60 mmol/L 71.8 (62.7–79.7) 42.8 (38.8–46.9) 5.0 (3.8–6.3) 5.8 (3.0–10.2)
Pancreatic sufficiency 52.5 (42.3–62.5)* 51.3 (47.2–55.4)* 25.3 (22.8–27.8)* 26.2 (19.9–34.0)*
Chronic PA (Transplants excluded) 14.6 (8.0–23.7)** 23.1 (19.3–27.3)** 28.2 (25.7–30.8)** 39.5 (32.0–47.0)**
Mean ± SD FEV1% pred (CI)
(Transplants excluded; ≥6 year)
92.1c22.2
(88.0–96.2)
74.2 ± 29.7
(71.8–76.6)
64.9 ± 27.1
(63.4–66.4)
65.1 ± 23.3
(61.7-68.5)
Lung transplant N (%) (CI) 13 (11.1)
(6.1–18.3)
63 (10.6)
(8.3–13.4)
NA 2 (1.1)
(0.1–3.8)
*% based on 101 *% based on all *% based on 1192 *% based on 164
**% based on 89 **% based on 484 **% based on all **% based on 173
NA = not available.
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patients with 2 CFTR mutations reported, but also the highest
proportion of patients with 1 or 2 CFTR mutations not listed as
disease causing in CFTR2 (Table 1). At the time of the study, only
France had already implemented nationwide neonatal screening
program. Therefore, more patients with non CF causing mutations
or mutations with various clinical consequences could have been
included in the registry. There is however little evidence that
French patients not meeting the diagnostic criteria come from the
newborn screen cohort, given the large proportion of adults and
the high median age and quartiles of these French patients.Table 4
Characteristics of the patients reported in 4 European CF patient registries. Percent (9
CF diagnosis documented (in italic) (sweat chloride N60 mmol/L or 2 CF causing m
Belgium Franc
N 1129 5640
1012 5047
Males 52.0 (49.0–54.9) 51.8
52.7 (49.5–55.8) 51.8
Median age (yr) (IQR) 18.8 (10.2–28.9) 16.5
18.8 (10.4–28.7) 15.9
≥18 year 51.5 (48.5–54.4) 45.9
51.8 (48.6–54.9) 44.3
Sweat chloride ≤60 mmol/L 8.4 (6.9–10.2) 6.9 (
1.1 (0.5–1.9) 2.7 (
F508del homozygous 45.9 (42.9–48.8) 43.6
51.2 (48.1–54.3) 48.7
Pancreatic sufficiency 14.6 (12.5–16.9)* 17.0
10.4 (8.5–12.6)+ 13.0
Chronic PA (Transplants excluded) 30.9 (28.0–33.9)** 24.8
32.6 (29.5–35.8)++ 25.0
Mean ± SD FEV1% pred (CI)
(Transplants excluded; ≥6 year)
81.4 ± 24.6
(80.0–82.8)
73.7
(73.0
80.2 ± 24.5
(78.7–81.7)
70.1
(69.4
Lung transplant N (%) (CI) 109 (9.6)
(8.0–11.5)
352 (
(5.6–
96 (9.5)
(7.8–11.5)
291 (
(5.1–
*% based on 1021 *% b
**% based on 967 **%
+% based on 920 +% b
++% based on 878 ++%Nationwide newborn screening could however explain the slightly
lower median age of subjects in the French registry. In Belgium,
the larger proportion of subjects with sweat chloride value
≤60 mmol/L as well as the phenotype of the subjects not
meeting the diagnostic criteria suggests inclusion of a larger
proportion of subjects with questionable CF diagnosis. So
overall, in this collection of registries, more complete reporting of
diagnostic tests in the French and Belgian registry seemed to be
associated with more frequent reporting (possibly overreporting) of
subjects with mild phenotype. On the contrary, patients with CF
diagnosis not documented in the Dutch and German registry seem5% CI) unless stated otherwise. All patients (in bold) versus only patients with
utations according to CFTR2 project).
e Germany The Netherlands
5054 1299
3824 1111
(50.5–53.1) 51.6 (50.2–52.9) 53.6 (50.8–56.3)
(50.4–53.2) 51.1 (49.6–52.7) 53.8 (50.8–56.8)
(8.0–25.8) 18.6 (10.7–27.5) 18.0 (9.8–29.6)
(7.7–24.7) 17.3 (9.9–26.1) 17.3 (9.8–27.7)
(44.6–47.2) 51.9 (50.6–53.3) 50.0 (47.3–52.8)
(42.9–45.7) 47.8 (46.2–49.3) 49.5 (46.5–52.5)
6.2–7.6) 2.1 (1.7–2.5) 1.7 (1.1–2.6)
2.2–3.1) 1.2 (0.9–1.6) 0.6 (0.3–1.3)
(42.3–44.9) 42.1 (40.7–43.4) 55.3 (52.5–58.0)
(47.3–50.1) 55.6 (54.0–57.2) 63.7 (60.8–66.6)
(16.0–18.0)* 14.7 (13.8–15.8)* 14.2 (12.4–16.3)*
(12.1–13.9)+ 11.4 (10.4–12.4)+ 12.8 (10.8–15.0)+
(23.6–26.0)** 28.4 (27.1–29.7)** 38.5 (35.7–41.3)**
(23.7–26.3)++ 28.5 (27.0–29.9)++ 36.0 (33.1–39.0 )++
± 28.5
–74.4)
69.3 ± 26.7
(68.6–70.0)
74.8 ± 26.2
(73.4–76.2)
± 26.9
–70.8)
70.8 ± 26.4
(70.0–71.6)
77.1 ± 25.1
(75.6–78.6)
6.2)
6.9)
NA 30 (2.3)
(1.6-3.3)
5.8)
6.4)
NA 28 (2.5)
ased on all *% based on 4921 *% based on 1204
based on 4984 **% based on all **% based on 1211
ased on all +% based on 3729 +% based on 1055
based on 4539 ++% based on all ++% based on 1028
280 M. Thomas et al. / Journal of Cystic Fibrosis 13 (2014) 275–280to be mainly older and sicker patients, more likely a consequence
of missing data.
The strengths of this paper are the fact that we are the first to
critically review the inclusion criteria of patients in CF registries.
The information on revoked diagnosis of CF in the German
registry also points towards the need of careful review of diagnosis
of subjects included in a specific patient registry [16]. The
weaknesses in this paper are those inherent to all registry studies.
Registries are collecting real life data. They are restrospective and
without rigorous quality control achievable in clinical trials.
Differences in findings can be real but can also be secondary to
methodological issues: missing data, lack of standardization of
definitions and data collection methods. The coverage and the
exhaustivity of data in national registries can be hard to assess.
Missing data like sweat test results in older patients can be
difficult to avoid. Lack of standardization of definitions
e.g. pancreatic insufficiency or chronic PA infection, can modify
the proportions of patients with these conditions. Data collections
methods can vary between countries: e.g. for lung function, some
registries report the best of the year, others the last of the year or
closest to the patient's birthday. The accuracy of quality control of
data in registries (missing, inconsistent data…) can impact strongly
on the output. Methods of diagnosis and particularly of
genotyping can also be widely different. Access to whole CFTR
gene sequencing can co-determine the number of patients with
rare mutations and potentially unknown clinical impact included
in registries.
In conclusion, this critical evaluation of 4 national CF
registries in Europe, demonstrates that more attention should
go to documentation of diagnostic test results. In addition, before
data in different registries can be used reliably for benchmarking,
the same diagnostic criteria should be applied so that similar
patient cohorts can be compared.Acknowledgments
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